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ABSTRACT 
Objective: To develop and validate the RP-HPLC method and in vitro dissolution study for escitalopram as antidepressant drug and their formulation. 
Methods: The chromatographic separation was done by using a C-18, 150 mm column and a mobile phase consisting of phosphate buffer (40%) 
and acetonitrile HPLC grade (60%). Detection was carried out at 211 nm with a flow rate of 1 ml/min with an injection of 20 μl. The method was 
validated with different parameters such as linearity, precision, accuracy, robustness, and limit of detection (LOD), the limit of quantification (LOQ) 
according to ICH guidelines. 
Results: The linear calibration curve was obtained in the concentration range of 0-50 μg/ml and gave an average correlation factor 0.992. The 
retention time was observed at 2.96 min. The Minimum concentration level at which the analyte can be reliably detected (LOD) and quantified 
(LOQ) were found to be 0.03 and 0.09 µg/ml, respectively. The relative standard deviation of intra and the inter-day assay was found to be less than 
2. The dissolution studies show moderate dissolution (23.4%) after 45 min, but it reaches a plateau after approximately 25 min. 
Conclusion: This method was found to be simple, rapid and economic with less run time. The validated parameters manifest the method is reliable, 
linear, accurate and precise as well as robust with minor variations in chromatographic parameters. Therefore, the developed method can be 
applied for both routine analysis and quality control assay and it could be a very powerful tool to investigate the stability of escitalopram. 
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INTRODUCTION 
Escitalopram is chemically (1S)-1-[3-(dimethylamino)propyl]-1-(4-
fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile. The typical 
chemical structure is shown in fig. 1. The drug having the molecular 
formula: C20H21FN2O•C2H2O4. Escitalopram is a selective serotonin 
reuptake inhibitor (SSRI). The S-enantiomer of racemic citalopram 
[1]. In the treatment of depression and anxiety, it is used to restore 
serotonergic functions. Escitalopram is approximately 150 times 
more potent than citalopram’s R-enantiomer. Amongst SSRIs, 
escitalopram exerts the highest degree of selectivity for the 
serotonin transporter (SERT) relative to others [2]. Escitalopram 
also differentiates itself from other SSRIs via allosteric action on its 
target; this may be the mechanism responsible for its observed 
superior efficacy and faster onset compared to other SSRIs.  
 
 
Fig. 1: Structure of escitalopram 
 
Literature survey reveals spectrophotometric, RP-HPLC [3-13], and 
HPTLC [14] methods for these compounds either individually or in 
combination with other dosage forms. The literature review does 
not show any stability indicating RP-HPLC method for quantification 
of escitalopram. Hence, it was felt that there was a need for a new 
analytical method by RP-HPLC. The present research work was 
aimed to develop a single, simple, fast, rapid suitable stability-
indicating RP-HPLC method for the determination of escitalopram. 
The developed method was validated concerning specificity, the 
limit of detection (LOD), the limit of quantitation (LOQ), linearity, 
precision, accuracy and robustness. The method is in the accordance 
with ICH guidelines [15-17]. 
MATERIALS AND METHODS 
Chemicals and reagents  
Samples of escitalopram pure drugs were received from, Cipla 
Limited (Mumbai, India). HPLC-grade acetonitrile was purchased 
from Merck (Mumbai, India). Ortho-phosphoric acid was purchased 
from Qualigens Fine Chemicals (Mumbai, India). HPLC grade water 
was prepared by using a Millipore Milli-Q plus purification system. 
HPLC instrumentation and conditions 
The HPLC system employed was Hitachi L2130 with D elite 2000 
Software with isocratic with UV-visible detector (L-2400). 
Standard and sample preparation for UV-spectrophotometer 
analysis 
The standard and sample stock solutions were prepared separately 
by dissolving standard and sample in a solvent in the mobile phase 
diluting with the same solvent. After the optimization of all 
conditions for UV analysis, it scanned in the UV spectrum in the 
range of 200 to 400 nm. This has been performed to know the 
maxima of escitalopram so that the same wavenumber can be 
utilized in HPLC UV detector for estimating the escitalopram. While 
scanning the escitalopram solution, we observed the maxima at 211 
nm. The UV spectrum has been recorded on ELICO SL-159 make UV-
Visible spectrophotometer model UV-2450. 
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Standard Solution preparation 
25 mg of escitalopram standard was transferred into 25 ml 
volumetric flask, dissolved and makeup to volume with mobile 
phase. Further dilution was done by transferring 1 ml of the above 
solution into a 10 ml volumetric flask and makeup to volume with 
mobile phase. 
Sample solution preparation 
20 tablets of the marketed drug were weighed and the average 
weight was calculated. The sample equivalent to 25 mg of 
escitalopram was accurately weighed and transferred into a 25 ml 
volumetric flask. About 20 ml of diluent was added and sonicated to 
dissolve drug completely and the volume was made up to the mark 
with diluent, which gave the stock solution of 1000 ppm. The 
solution was mixed well and filtered through a 0.45 µm filter. 1 ml of 
the above stock solution was pipetted into a 10 ml volumetric flask 
and diluted up to the mark with diluent to prepare 100 ppm 
solution. Further 1 ml of prepared 100 ppm solution was pipetted 
into a 10 ml volumetric flask and diluted up to the mark with 
diluent, which gave 10 ppm escitalopram working standard solution. 
It was mixed well and filtered through a 0.45 µm filter. 
Preparation of phosphate buffer 
About 6.8 gm of potassium dihydrogen orthophosphate was 
weighed and transferred into a 1000 ml beaker, dissolved and 
diluted to 1000 ml with HPLC water. The pH was adjusted to 3.0 
with orthophosphoric acid. 
Preparation of the mobile phase 
400 ml (40%) of the above buffer and 600 ml of acetonitrile HPLC 
(60%) were mixed well and degassed in an ultrasonic water bath for 
15 min. The solution was filtered through a 0.45 μm filter under 
vacuum filtration [18]. 
Diluent preparation: Mobile phase as diluent. 
RESULTS 
Initialization of the instrument 
The HPLC instrument was switched on. The column was washed 
with HPLC water for 45 min. The column was then saturated with 
the mobile phase for 45 min. The mobile phase was run to find the 
peaks. After 20 min the standard drug solution was injected in HPLC. 
 
 
Fig. 2: Chromatogram escitalopram 
 
Table 1: Optimized chromatographic conditions 
Column:  C18 Develosil ODS HG-5 RP 150 mm x4.6 mm 5 μm particle size 
Mobile Phase:  Buffer: Acetonitrile (60;40) (pH 2.9) 
Flow Rate:  1.0 ml/min 
Wavelength:  211 nm 
Injection volume:  20 μl 
Run time:  10 min 
Column temperature:  Ambient 
 
Table 2: Different trials for chromatographic conditions 
Column used Mobile phase Flow rate Wavelength Observation Result 
Waters C18, 5m, 25 cmx4.6 mm i.d. Methanol: Water = 80: 20 0.5 ml/min 211 nm Low response Method rejected 
Waters C18, 5m, 25 cmx4.6 mm i.d. ACN only 0.5 ml/min 211 nm Very low response Method rejected 
Waters C18, 5m, 25 cmx4.6 mm i.d. ACN: water = 50: 50 1.0 ml/min 211 nm Tailing peak Method rejected 
Waters C18, 5m, 25 cmx4.6 mm i.d. ACN: acetate buffer = 50:50 1.0 ml/min 211 nm Broad Peak Method rejected 
Waters C18, 5m, 25 cmx4.6 mm i.d. ACN: phosphate buffer = 
60:40 (pH 2.9) 
1.0 ml/min 211 nm Good response Method accepted 
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Method validation  
Accuracy and recovery study  
To determine the accuracy of the proposed method, recovery studies 
were carried out by adding different amounts (80%, 100%, and 120%) 
of pure drug of escitalopram were taken and added to the pre-analyzed 
formulation of concentration 10 g/ml. From that percentage, recovery 
values were calculated. The results were shown in table 3. 
Precision 
As per USP, it is the degree of agreement among individual test 
results obtained upon repeated application of analytical methods to 
multiple samplings of a homogenous sample or measure of the 
extent to which the data values are close to each other for many 
measurements (under similar conditions). 
Preparation of working standard of 10 ppm of escitalopram 
25 mg of escitalopram working standard was accurately weighed 
and transferred into a 25 ml volumetric flask, and about 20 ml of 
diluent was added to it and sonicated to dissolve drug 
completely and volume was made up to the mark with the same 
solvent which gave a Stock solution of 1000 ppm. 1 ml of the 
above stock solution was pipetted into a 10 ml volumetric flask 
and was diluted up to the mark with diluents to prepare 100 
ppm solution. Further 1 ml of prepared 100 ppm solution was 
pipetted into a 10 ml volumetric flask and was diluted up to the 
mark with diluents, which gave 10 ppm escitalopram working 
standard solution. The solution was mixed well and filtered 
through a 0.45 µm filter. 
Procedure 
The standard solution was injected for five times and measured the 
area for all five injections in HPLC. The %RSD for the area of five 
replicate injections was found to be within the specified limits. 
Acceptance criteria 
The % RSD for the area of five standard injections results should not 
be more than 2%. 
 
Table 3: Accuracy study of escitalopram 
Sample ID Concentration (g/ml) % recovery of 
pure drug 
Statistical analysis 
Pure drug Formulation 
S1: 80 % 8 10 99.13 Mean*= 98.94667% 
SD = 0.171561 
% R. SD= 0.1733 
S2: 80 % 8 10 98.79 
S3: 80 % 8 10 98.92 
S4: 100 % 10 10 99.72 Mean*= 99.76% 
SD = 0.045826 
% R. SD= 0.0459 
S5: 100 % 10 10 99.81 
S6: 100 % 10 10 99.75 
S7: 120 % 12 10 99.36 Mean*= 99.37667% 
SD = 0.105987 
% R. SD = 0.1066 
S8: 120 % 12 10 99.28 
S9: 120 % 12 10 99.49 
*mean assay values of 3 replicates (n=3). 
 























































a) marovirac130 - Vial 1 Inj 1 marovirac ki - Channel 1
b) marovirac130 - Vial 1 Inj 1 marovirac ki - Channel 1
c) marovirac130 - Vial 1 Inj 1 marovirac ki - Channel 1
d) marovirac130 - Vial 1 Inj 1 marovirac ki - Channel 1
e) marovirac130 - Vial 1 Inj 1 marovirac ki - Channel 1
 
Fig. 3: Repeatability for escitalopram 
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Table 4: Precision results 
HPLC injection replicates of escitalopram Retention time Area 
Replicate–1 2.96 1025457 
Replicate–2 2.94 1003224 
Replicate–3 2.97 995798 
Replicate–4 2.96 992259 
Replicate–5 2.97 998740 
Average 2.958 1003096 
Standard Deviation* 0.013038 13131.13 
% RSD 0.440784 1.309061 
 *Standard deviation (n=5) calculated in five replicates. 
 
Table 5: Results of intra-assay and inter-assay 
Conc. of escitalopram 
(API) (µg/ml) 
Observed Conc. of escitalopram (µg/ml) by the proposed method  
Intra-day assay Inter-day assay 
Mean* (n=6) % RSD Mean* (n=6) % RSD 
10 10.01 0.86  10.03 0.87 
30 30.02 0.30 30.03 0.32 
100 99.97 0.13 99.95 0.11 
*Mean (n=6) 
 
Intra-assay and inter-assay 
The intra and inter-day variation of the method was carried out and 
the high values of mean assay and low values of standard deviation 
and % RSD (% RSD<2%) within a day and day to day variations for 
escitalopram revealed that the proposed method is precise. 
Linearity and range 
Linearity indicates the ability of analytical procedures to produce 
results that are directly proportional to the concentration of analyte 
in the given sample. 
Preparation of stock solution (100 ppm) 
25 mg of escitalopram was dissolved in 25 ml of the mobile phase, 
which gave a solution of the strength of 1000 ppm. 1 ml of this 
solution was pipetted into a 10 ml volumetric flask and the volume 
was made up to mark with diluents (mobile phase), which finally 
gave the stock solution of the strength of 100 ppm. The stock 
solution was degassed in an ultrasonic water bath for 5 min and 
filtered through a 0.45 µm filter under vacuum filtration. 
Procedure 
Each level was injected into the chromatographic system and the 
peak area was measured. A graph of peak area versus concentration 
(on X-axis concentration and Y-axis peak area) was plotted and the 
correlation coefficient was calculated. 
Acceptance criteria 
Correlation coefficient should be not less than 0.999. 
Calibration curve 
Linearity plot information 
 
Fig. 4: Calibration curve of escitalopram (API) 
 
The calibration curve showed good linearity in the range of 0-50 
µg/ml, for escitalopram (API) with a correlation coefficient (r2) of 
0.992 (fig. 4). A typical calibration curve has the regression equation 
of y = 26474x+40986 for escitalopram. 
 
Table 6: Linearity results 








Method robustness  
Influence of small changes in chromatographic conditions such as a 
change in flow rate ( 0.1 ml/min), temperature (2 °C), the 
wavelength of detection (2 nm) and acetonitrile content in the 
mobile phase (2%) studied to determine the robustness of the 
method are also in favour of (table 7, % RSD<2%) the developed RP-
HPLC method for the analysis of escitalopram (API). 
LOD and LOQ  
The minimum concentration level at which the analyte can be 
reliably detected (LOD) and quantified (LOQ) were found to be 0.03 
and 0.09 µg/ml, respectively. 
Assay of escitalopram in dosage form 
Twenty tablets containing drug escitalopram having brand name 
Cipralex-10 mg were taken and the I. P. method was followed to 
determine the average weight. Above weighed tablets were finely 
powdered and triturated well. A quantity of powder equivalent to 
100 mg of drugs was transferred to 100 ml volumetric flask, and 70 
ml of diluents was added and the solution was sonicated for 15 min, 
thereafter volume was made up to 100 ml with the same solvent. 
Then 10 ml of the above solution was diluted to 100 ml with 
diluents. The solution was filtered through a membrane filter (0.45 
m) and sonicated to degas. From this stock solution (1 ml) was 
transferred to five different 10 ml volumetric flasks and volume 
were made up to 10 ml with the same solvent system. The solution 
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prepared was injected in five replicates into the HPLC system and 
the observations were recorded. A duplicate injection of the 
standard solution was also injected into the HPLC system and the 
peak areas were recorded. The data are shown in table 8. 
 
Table 7: Result of the method robustness test 
Change in parameter % RSD 
Flow (1.1 ml/min) 0.06 
Flow (0.9 ml/min) 0.04 
Temperature (27 °C) 0.08 
Temperature (23 °C) 0.11 
Wavelength of detection (213 nm) 0.03 
Wavelength of detection (209 nm) 0.02 
 *% RSD<2% 
 
Table 8: Assay of escitalopram tablets 
Brand name of the tablet 
 
Labelled amount of drug (mg) Mean (SD) amount (mg) found 
by the proposed method (n=6)  
Mean (SD) assay (n = 6) 
Cipralex-10 mg  10 09.34 (0.06) 99.56 (0.48) 







































Fig. 5: Chromatogram showing peak of escitalopram in tablet formulation 
 
Dissolution profile 
Dissolution was done according to USP using the paddle dissolution 
apparatus. The dissolution test was performed in three different pH 
media of 1.2 (0.1N HCl), 4.5 and 6.8 phosphate buffer. The 
dissolution profiles were performed for the two prepared formulae 
to select the best 
f2= 50 log {[1+(1\n)Sn (R-T)2]-0.5 ×100}. (1)  
f1= {[Sn |R-T |]/[Sn R ]}x100.  (2) 
 
Table 9: Dissolution data of escitalopram 











*% dissolution studies done with (n=10) with respect to time in min, the result shows a moderate dissolution (23.4%) after 45 min, but it reaches a 
plateau after approximately 25 min. 
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Fig. 6: Dissolution profile w. r. t. time 
 
DISCUSSION 
The various RP-HPLC methods have been studied for the analysis of 
escitalopram in bulk and various dosage forms [3-13]. However, the 
reported methods are less specific and also time-consuming. 
Therefore, we tried to develop a simple RP-HPLC method for the 
determination of escitalopram in bulk and its dosage form and also 
worked on the dissolution studies. 
The sample preparation is a key step for accurate and reliable 
methods. The phosphate buffer is prepared by using potassium 
dihydrogen orthophosphate and the orthophosphoric acid is used to 
adjust the required pH. We have taken almost five trials with 
different types of mobile phases and out of that we have selected the 
ACN: phosphate buffer = 60:40 (pH 2.9) mobile phase, as it has given 
the good response as compare to the other methods, the indicative 
chromatogram is shown in the fig. 2. The separation was carried out 
by C-18, 150 mm column using mobile phase made up of phosphate 
buffer (40%) and acetonitrile HPLC grade (60%), the wavelength 
used is 211 nm with a flow rate of 1 ml/min and the injection 
volume 20 μl. The developed method was validated with different 
parameters such as linearity, precision, accuracy, robustness, the 
limit of detection (LOD), and limit of quantification (LOQ) according 
to ICH guidelines [15-17].  
In the accuracy study, the SD found to be 0.171561, 0.045826, and 
0.105987 the samples are analyzed in three replicates. The recovery 
study indicates that the average recovery is 99.36%. The precision 
results also hold the passing criteria, and which is taken in five 
replicates % RSD for the area of five standard injections results is not 
more than 2%. The result of intra-assay and inter-assay shown in table 
no. 5 also confirms that the proposed method is precise. The linearity 
plot indicates good linearity in the concentration range of 0-50 µg/ml, 
with a correlation coefficient (r2) of 0.992. A typical calibration curve 
has the regression equation of y = 26474x+40986 is shown in fig. 4. 
The effect of small changes in chromatographic conditions such as 
the change in flow rate (±0.1 ml/min), temperature (±2 °C), the 
wavelength of detection (±2 nm) and acetonitrile content in the 
mobile phase (±2%) also studied to determine the robustness of the 
method, and are also in favour of developed method. The limit of 
detection (LOD) and limit of quantification (LOQ) were found to be 
0.03 and 0.09 µg/ml, respectively. As compared to the other 
developed methods the intra and inter-day assay was given a good 
result and it is found to be less than 2. The assay of tablets 
containing escitalopram was found to be 99.56 %. The fig. 5 shows 
the chromatogram of the tablet dosage form. The dissolution test 
was performed in three different pH media of 1.2 (0.1N HCl), 4.5 and 
6.8 phosphate buffer respectively, and the study shows a moderate 
dissolution (23.4%) after 45 min, but it reaches a plateau after 
approximately 25 min. Fig. 6 indicates the graphic representation of 
the dissolution study with respect to time (min). 
CONCLUSION 
The RP-HPLC method was developed for the analysis of 
escitalopram in standard and their pharmaceutical formulation and 
is found to be simple, rapid and economic with less run time. The 
method has been validated and it has been shown that it is reliable, 
linear, accurate and precise as well as robust with minor variations 
in chromatographic parameters. The in vitro dissolution results 
show a moderate dissolution (23.4%) after 45 min, but it reaches a 
plateau after approximately 25 min. Therefore, it will be applied for 
both routine analysis and quality control assay and it could be a very 
powerful tool to investigate the stability of escitalopram. 
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